Cargando…

Role of natriuretic peptide receptor C signalling in obesity-induced heart failure with preserved ejection fraction with pulmonary hypertension

Detalles Bibliográficos
Autores principales:	Eroume-A Egom, Emmanuel, Kamgang, Rene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052478/ https://www.ncbi.nlm.nih.gov/pubmed/32166021 http://dx.doi.org/10.1177/2045894020910975

Ejemplares similares

Natriuretic Peptide Clearance Receptor (NPR-C) Pathway as a Novel Therapeutic Target in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF)
por: Egom, Emmanuel Eroume A.
Publicado: (2021)

Authors’ reply: role of natriuretic peptide receptor C signalling in obesity-induced heart failure with preserved ejection fraction with pulmonary hypertension
por: Agrawal, Vineet, et al.
Publicado: (2020)

Identifying Potential Mutations Responsible for Cases of Pulmonary Arterial Hypertension
por: Egom, Emmanuel Eroume-A, et al.
Publicado: (2021)

Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides
por: Meijers, W. C., et al.
Publicado: (2016)

Marked elevation of B-type natriuretic peptide in patients with heart failure and preserved ejection fraction
por: Tate, Samuel, et al.
Publicado: (2014)

Natriuretic Peptide Levels and Stages of Left Ventricular Dysfunction in Heart Failure with Preserved Ejection Fraction
por: Dal Canto, Elisa, et al.
Publicado: (2023)

Natriuretic peptide receptor C contributes to disproportionate right ventricular hypertrophy in a rodent model of obesity-induced heart failure with preserved ejection fraction with pulmonary hypertension
por: Agrawal, Vineet, et al.
Publicado: (2019)

Efficacy of exogenous atrial natriuretic peptide in patients with heart failure with preserved ejection fraction: deficiency of atrial natriuretic peptide and replacement therapy
por: Matsumoto, Shingo, et al.
Publicado: (2020)

Pulmonary Arterial Hypertension Due to NPR-C Mutation: A Novel Paradigm for Normal and Pathologic Remodeling?
por: Egom, Emmanuel Eroume-A
Publicado: (2019)

Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications
por: Tanase, Daniela Maria, et al.
Publicado: (2019)

Usefulness of B‐Type Natriuretic Peptide for Predicting the Risk of Stroke in Patients With Heart Failure With Preserved Ejection Fraction
por: Liu, Xiao, et al.
Publicado: (2022)

Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial( )
por: Dachs, Theresa Marie, et al.
Publicado: (2022)

Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors
por: Ovchinnikov, Artem, et al.
Publicado: (2022)

Sarcopenic Obesity in Heart Failure With Preserved Ejection Fraction
por: Kirkman, Danielle L., et al.
Publicado: (2020)

Natriuretic peptides for the detection of diastolic dysfunction and heart failure with preserved ejection fraction—a systematic review and meta-analysis
por: Remmelzwaal, Sharon, et al.
Publicado: (2020)

Pulmonary Hypertension in Patients with Heart Failure with Preserved Ejection Fraction. Where to Draw the Line
por: Simon, Marc A., et al.
Publicado: (2019)

Diffuse right ventricular fibrosis in heart failure with preserved ejection fraction and pulmonary hypertension
por: Patel, Ravi B., et al.
Publicado: (2020)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

From acute SARS-CoV-2 infection to pulmonary hypertension
por: Eroume À Egom, Emmanuel, et al.
Publicado: (2022)

Midregional pro-atrial natriuretic peptide is a superior biomarker to N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure patients with preserved ejection fraction
por: Cui, Kun, et al.
Publicado: (2018)

Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension
por: Codina, Pau, et al.
Publicado: (2022)

Poor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fraction
por: Bourji, Khalil I., et al.
Publicado: (2017)

Independent predictors of developing pulmonary hypertension in heart failure with reduced versus preserved ejection fraction
por: Roushdy, Alaa, et al.
Publicado: (2017)

Highest Obesity Category Associated With Largest Decrease in N‐Terminal Pro‐B‐Type Natriuretic Peptide in Patients Hospitalized With Heart Failure With Preserved Ejection Fraction
por: Vaishnav, Joban, et al.
Publicado: (2020)

Pregnancy and breastfeeding during COVID-19 pandemic
por: Egom, Emmanuel Eroume-A, et al.
Publicado: (2020)

Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction
por: Altara, Raffaele, et al.
Publicado: (2017)

Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity
por: Dhore-patil, Aneesh, et al.
Publicado: (2022)

Obesity, Preserved Ejection Fraction Heart Failure, and Left Ventricular Remodeling
por: Stencel, Jason, et al.
Publicado: (2023)

Diagnosing heart failure with preserved ejection fraction with pulmonary vascular disease
por: Maeder, Micha T
Publicado: (2023)

Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016)

Management of heart failure with preserved ejection fraction
por: Gard, Emma, et al.
Publicado: (2020)

Managing heart failure with preserved ejection fraction
por: Davidson, Alexander, et al.
Publicado: (2020)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Comorbidities in heart failure with preserved ejection fraction
por: Deichl, Andrea, et al.
Publicado: (2022)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Reduction of Pulmonary Hypertension After Transition to Sacubitril/Valsartan in Patients With Heart Failure With Preserved Ejection Fraction
por: Burgdorf, Christof, et al.
Publicado: (2021)

Exercise Systolic Reserve and Exercise Pulmonary Hypertension Improve Diagnosis of Heart Failure With Preserved Ejection Fraction
por: Verwerft, Jan, et al.
Publicado: (2022)

Improved hospitalization rates in a specialty center for heart failure with preserved ejection fraction and pulmonary hypertension
por: Kosanovich, Chad M., et al.
Publicado: (2022)

Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial
por: Pandey, Ambarish, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m0j096rou2ulvgqd1gj2b4c4sa